Table 1.
Sociodemographic and clinical characteristics glioma cohort and longitudinal subgroup
| Glioma cohort (N = 222) | Longitudinal subgroup (n = 70) | |
|---|---|---|
| Age, mean (SD) | 45.6 (13.3) | 41.0 (11.6) |
| Sex, n (%) | ||
| Male | 126 (56.8%) | 42 (60.0%) |
| Female | 96 (43.2%) | 28 (40.0%) |
| Level of education (Verhage), n (%) | ||
| Low (1–4) | 41 (18.5%) | 11 (15.7%) |
| Middle (5) | 75 (33.8%) | 26 (37.1%) |
| High (6–7) | 106 (47.7%) | 32 (45.7%) |
| Missing | 1 (1.4%) | |
| Tumor hemisphere, n (%) | ||
| Left | 137 (61.7%) | 46 (65.7%) |
| Right | 81 (36.5%) | 23 (32.9%) |
| Both | 4 (1.8%) | 1 (1.4%) |
| Tumor location, n (%) | ||
| Frontal | 132 (59.5%) | 41 (58.6%) |
| Non-frontal | 90 (40.5%) | 29 (41.4%) |
| WHO grade, n (%) | ||
| II | 114 (51.4%) | 47 (67.1%) |
| III | 60 (27.0%) | 20 (28.6%) |
| IV | 48 (21.6%) | 3 (4.3%) |
| Tumor type, n (%) | ||
| Oligodendroglioma | 74 (33.3%) | 33 (47.1%) |
| Astrocytoma, IDH mutated | 67 (30.2%) | 24 (34.3%) |
| Astrocytoma, IDH wildtype | 10 (4.5%) | 3 (4.3%) |
| Astrocytoma, IDH status unknown | 14 (6.3%) | 3 (4.3%) |
| Oligoastrocytoma* | 9 (4.1%) | 4 (5.7%) |
| Glioblastoma, IDH mutated | 5 (2.3%) | 1 (1.4%) |
| Glioblastoma, IDH wildtype | 21 (9.5%) | 2 (2.9%) |
| Glioblastoma, IDH status unknown | 22 (9.9%) | 0 (0%) |
| Using anti-epileptic drugs, n (%) | ||
| No | 5 (2.3%) | 1 (1.4%) |
| Yes | 163 (73.4%) | 52 (74.3%) |
| Missing | 54 (24.3%) | 17 (24.3%) |
| Number of included assessments per patient, n (%) | ||
| 1 | 137 (61.7%) | |
| 2 | 68 (30.3%) | 70 (100%) |
| 3 | 10 (4.5%) | |
| 4 | 6 (2.7%) | |
| 6 | 1 (0.5%) |
Abbreviations: SD, standard deviation; n, number.
*Histological diagnosis of these patients was based on the 2007 WHO classification of the central nervous system tumors, and could not be re-classified because molecular markers were not available50.